EE286 Post-Infusion Monitoring Costs By Site of Care Among Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) Who Received Second-LINE Treatment with Lisocabtagene Maraleucel (LISO-CEL) in the Transform Study: A United States ...
Jul 1, 2022, 00:00 AM
10.1016/j.jval.2022.04.531
https://www.valueinhealthjournal.com/article/S1098-3015(22)00732-X/fulltext
Section Title :
Section Order :
10471
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00732-X&doi=10.1016/j.jval.2022.04.531